Dare Greatly: Enter the Arena

Endothelial Progenitor Cells Enter the Aging Arena

Age is a significant risk factor for the development of vascular diseases, such as atherosclerosis. Although pharmacological treatments, including statins and anti-hypertensive drugs, have improved the prognosis for patients with cardiovascular disease, it remains a leading cause of mortality in those aged 65 years and over. Furthermore, given the increased life expectancy of the population in ...

Poststroke cognition and the fight against the hard problem: vascular neurologists, enter the arena!

See related article, pages 198–203 In this issue of Stroke, Snaphaan and de Leeuw report on their results obtained from a systematic review on poststroke memory dysfunction.1 Of the 798 articles their search strategy identified, only 5 mentioned memory testing at different poststroke intervals, only 3 studies followed patients for at least 1 year, whereas the largest study contained only 196 pa...

Revisiting the Network of Drug-Eluting Stent Trials: Bioresorbable Scaffolds Enter the Arena.

SEE PAGE 1203 T en years ago, during the annual European Society of Cardiology meeting in Barcelona, 2 independent meta-analyses suggested that drug-eluting stents (DES), despite being more effective than bare-metal stents (BMS) in reducing restenosis, increase mortality due to very late thrombosis (1). However, this was no longer confirmed by a plethora of randomized controlled trials (RCTs) a...

MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

Coronary artery disease (CAD) and its complication remain the leading cause of mortality in industrialized countries despite great advances in terms of diagnosis, prognosis, and treatment options. MicroRNAs (miRNAs), small noncoding RNAs, act as posttranscriptional gene expression modulators and have been implicated as key regulators in several physiological and pathological processes linked to...

The Arena: December 1966: Arena